Vision RT increases access to high quality surface guided radiotherapy with new systems installed at GenesisCare centres in the UK and Spain
18 December 2018. LONDON, UK- GenesisCare, one of the largest radiotherapy service providers in the world, has in recent months purchased numerous surface guided radiation therapy (SGRT) systems from Vision RT. Following an initial clinical rollout of AlignRT in the UK at its Nottingham and Oxford clinics, GenesisCare has installed additional systems in the UK, Spain and in the coming months into Australia.
The AlignRT system tracks a patient’s position before and during radiation therapy, to aid set-up and treatment accuracy, and can be used for a wide range of conditions including breast, brain, lung, liver, sarcoma, head and neck and other cancers.
GenesisCare’s Service Development Manager for Europe, Jacqui Dorney, said that delivering a positive patient experience and clinical outcomes was behind the decision to install the new systems.
“As the first provider in Europe to widely adopt this technology, we found that SGRT enhanced patient safety and comfort, and also boosted treatment accuracy across a wide range of indications including stereotactic body radiation therapy (SBRT), stereotactic radiosurgery (SRS) and deep inspiration breath hold (DIBH). SGRT for DIBH provides a patient-friendly technical solution for heart sparing for left-sided breast cancer patients, and also immobilises tumours in the lung and abdomen.
“Importantly, this technology also enables us to eliminate the need for patients to have permanent marks tattooed on their bodies. These small marks historically helped us to ensure accuracy during treatment, but sometimes left an unwanted reminder of a patient’s cancer journey,” said Ms Dorney.
GenesisCare has increased patient access to this technology over the past year, and now uses AlignRT across six centres in Europe.
Aldo Rolfo, GenesisCare’s Executive Manager of Europe, said: “GenesisCare is committed to providing the best possible treatments to all our patients. SGRT supports this goal, offering improved outcomes, efficiency and patient comfort. We expect SGRT to become the standard of care throughout our global network of cancer centres to ensure that we can deliver radiation therapy to the highest possible standards. We look forward to procuring additional systems for our growing number of linear accelerators,” he said.
Norman Smith, CEO at Vision RT, comments: “GenesisCare’s assessment of alternatives for SGRT has been one of the most rigorous and intensive we have ever seen. We are delighted that they have chosen to install numerous systems within their network, and look forward to our ongoing and deepening collaboration.”
###
About Vision RT
Vision RT defines the standard of care in Surface Guided Radiation Therapy. We provide superior solutions for the radiotherapy market, with products installed in many of the leading treatment centers in the world, including around 70% of the 50 US News “Best Hospitals for Cancer”. With 70 granted patents plus 51 pending, we continue to innovate in the radiation oncology space and are committed to making SGRT the standard of care for all patients, worldwide.
Vision RT is part of the William Demant Invest (WDI) family, a leading Danish Medtech investor with a long-term investment perspective. The companies in William Demant Invest employed on average 17,024 people during 2017 with a total revenue of $3bn.
About GenesisCare
GenesisCare delivers treatment to people with cancer and heart disease, the two largest disease burdens globally. We’re committed to leading the change in how care is designed and given, and are currently leading or participating in more than 100 clinical trials.
The organisation employs more than 2,500 highly trained healthcare professionals and support staff across Australia, Europe and now China, including some of the world’s most experienced specialists. Every year GenesisCare clinical teams see more than 160,000 people at more than 130 locations. For cancer treatment, that includes 12 centres in the UK, 21 in Spain and 30 in Australia, with more than 20 new centres under development. We also offer cardiology and sleep services at more than 80 locations across Australia.
Our purpose is to design care experiences that get the best possible life outcomes. We believe that care should be focused on the individual, not the condition, and are proud of our patient satisfaction ratings, which place us in the top 1 per cent of outpatient healthcare organisations in the world. For more information visit www.genesiscare.com